Puberty Blockers for Gender-Affirming Care: What Families Should Know

Puberty blockers (GnRH agonists) (e.g., leuprolide, histrelin, triptorelin) reversibly suppress pituitary gonadotropins (LH/FSH), pausing pubertal development. Used in transgender/gender-diverse youth with gender dysphoria.

Indications & Timing

  • Tanner stage 2–3 (early puberty) – ideally before irreversible changes.
  • Persistent, well-documented gender dysphoria.
  • Comprehensive mental health assessment.
  • Informed consent/assent from youth + parents/guardians.
  • Per WPATH SOC-8 & Endocrine Society guidelines.

Effects

  • Halts: breast growth, menstruation, voice deepening, facial/body hair, genital growth.
  • Prevents distress from unwanted secondary sex characteristics.
  • Buys time for gender exploration without pressure.
  • Reversible: stopping allows endogenous puberty to resume.

Side Effects & Monitoring

  • Bone Density: Reduced accrual during treatment. Monitor DXA; ensure calcium/vitamin D/weight-bearing exercise. Usually recovers after stopping or starting gender-affirming hormones.
  • Hot Flashes, Mood Changes, Fatigue, Headaches.
  • Metabolic: Weight gain, insulin sensitivity changes—monitor.
  • Fertility: Blockers alone don't cause infertility, but subsequent gender-affirming hormones may. Discuss fertility preservation (gamete cryopreservation) before starting hormones.

Controversies & Evidence

  • Long-term bone/brain effects under study.
  • Regulatory restrictions in some jurisdictions (UK, Sweden, Finland, several US states).
  • Major medical associations (AAP, AMA, Endocrine Society, WPATH) support access with multidisciplinary care.

Decision-Making

Individualized, family-centered, with experienced gender clinic. Not a standalone treatment—part of comprehensive gender-affirming care.

Teen Health - Related Articles